Investigational drug · Phase 2
HR19042
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Autoimmune Hepatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 24, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "HR19042"
First trial start
2022
Oct 6, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HR19042", any sponsor or status.
Conditions studied
As listed on its trial records.
- Autoimmune Hepatitis
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "HR19042" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.Pivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05016323 · 316 participants · Start Sep 9, 2021 · Primary completion Jun 9, 2024
Drug: HR19042 Capsules; Placebo · For: IgA Nephropathy
Sites: Guangzhou, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05476900 · 69 participants · Start Oct 6, 2022 · Primary completion Mar 14, 2025
Drug: HR19042 Capsules · For: Autoimmune Hepatitis
Sites: Shanghai, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06922305 · 18 participants · Start Dec 27, 2023 · Primary completion Jan 25, 2024
Drug: HR19042 Capsule, Tarpeyo®, Budenofalk® · For: Primary IgA Nephropathy; Autoimmune Hepatitis
Sites: Chengdu, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04887532 · 12 participants · Start Jul 1, 2021 · Primary completion Jul 27, 2021
Drug: HR19042 capsule · For: Primary IgA Nephropathy
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Comparison of the Pharmacokinetics of Three Budesonide Formulations in Healthy Chinese Subjects.
Yin T, Zou J, Tang M, et al. · Clin Pharmacol Drug Dev 2026
Also in development for Autoimmune Hepatitis
- zetomipzomibKZR-616, zetomipzomib in open-label extensionPhase 21 trial
Kezar Life Sciences, Inc. · Autoimmune Hepatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.